Monograph Details
|
|
Infections & Infestations
> Tuberculosis
|
|
CAPASTAT |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antibiotic. |
| Generic Name |
|
Capreomycin (as sulfate) 1g/vial; pwd for IV infusion after reconstitution and dilution, or IM inj after reconstitution. |
| Indications |
|
Adjunct in susceptible tuberculosis when first-line agents (INH, rifampin, ethambutol, aminosalicylic acid, streptomycin) are inappropriate. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over 1 hour or deep IM inj. 1g (max 20mg/kg) daily for 60–120 days, then 1g (max 20mg/kg) 2–3 times per week; max 20mg/kg per day. Treat for 12–24 months. Renal dysfunction: reduce dose (see literature). |
| Precautions |
|
Renal or auditory impairment. Monitor vestibular and auditory function at baseline and during therapy. Monitor renal function at baseline and during therapy; reduce dose or discontinue if BUN>30mg/dL or if renal function decreases. Monitor hepatic function and serum potassium. Elderly. Pregnancy (Cat.C; teratogenic; see literature). Nursing mothers. |
| Interactions |
|
Concomitant streptomycin, other parenteral antituberculars: not recommended. Increased toxicity with other neuro/ototoxic drugs (eg, aminoglycosides). |
| Adverse Reactions |
|
Neurotoxicity (esp. ototoxicity), renal toxicity, leukocytosis, leukopenia, abnormal liver function tests, inj site reactions (eg, pain, induration, bleeding), rash. |
| How Supplied |
|
Vial (10mL)—1 |
|
|
|
|
